** Shares of Argenica Therapeutics rise as much as 12% to A$0.745, logs biggest intraday pct gain since Aug. 14
** Drug developer reports positive results in safety studies required for Investigational New Drug application $(IND.AU)$ by the U.S. FDA for its ARG-007 drug, aimed at treating acute ischemic stroke, a form of brain stroke
** IND application is a request for authorisation to administer experimental drugs to humans
** Co says opening an IND will enable it to conduct later stage clinical trials in the U.S.
** Stock up 36.3% YTD, as at 0551 GMT
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.